Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01665092 · ClinicalTrials.gov registry record · Phase 2
Rapid Administration of Carnitine in sEpsis
A Phase 2 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT01665092 is a Phase 2 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 250 participants.
The verdict
NCT01665092, a Phase 2 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
Prior work has shown that exogenous L-carnitine administration enhances glucose and lactate oxidation, attenuates fatty acid toxicity, and improves endothelial-smooth muscle coupling and cardiac mechanical efficiency. The overall goal of this proposal is to investigate L-carnitine as a novel adjunctive treatment of septic shock. In this study the investigators will test our primary hypothesis: Early adjunctive L-carnitine administration in vasopressor dependent septic shock will significantly reduce cumulative organ failure at 48 hours with an associated decrease in 28-day mortality suggesting the need for further phase III study. To accomplish this the investigators will conduct a phase II, double blinded, placebo controlled, adaptive randomized trial of 250 eligible patients with vasopressor-dependent septic shock. Study subjects will be assigned to one of four arms: low (6g), medium (12g) or high (18g) dose intravenous L-carnitine or placebo for 12 hours as a part of early resuscitative care.
Interventions
- DRUG placebo
- DRUG Levo-Carnitine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2013-01 |
| Est. Completion | 2019-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01665092
The ClinicalTrials.gov registry entry for NCT01665092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01665092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01665092 about?
NCT01665092 is a clinical study titled "Rapid Administration of Carnitine in sEpsis". Prior work has shown that exogenous L-carnitine administration enhances glucose and lactate oxidation, attenuates fatty acid toxicity, and improves endothelial-smooth muscle coupling and cardiac mechanical efficiency. The overall goal of this proposal is to investigate L-carnitine as a novel adjunct...
What is the current status of trial NCT01665092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2013-01. Estimated completion is 2019-03.
What interventions are being tested in trial NCT01665092?
The interventions under investigation include: placebo (DRUG), Levo-Carnitine (DRUG).
Who is sponsoring clinical trial NCT01665092?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.